AEterna Zentaris (AEZS) Appoints Phil Theodore As Chief Administrative Officer, General Counsel And Corporate Secretary

QUÉBEC CITY, Oct. 7, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the appointment of Philip A. Theodore, as Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary. Before joining Aeterna Zentaris, Mr. Theodore was Vice President, General Counsel and Corporate Secretary of Zep Inc., a leading consumable chemical packaged goods company.

"We are very proud to welcome Philip to our leadership team, as he will be responsible for overseeing the day-to-day duties with respect to the administrative, legal, human resources, corporate development and corporate secretary functions. In developing his career, Philip has held increasingly responsible positions with several leading companies. He has extensive experience in merger and acquisition activities, integration of companies, management of numerous litigation matters as well as in counselling corporate management in regards to credit agreement negotiations, corporate disclosure issues and general contract issues", said David Dodd, Chairman and CEO of Aeterna Zentaris. "In his role, Phil will be an invaluable asset in establishing the platform for value growth and development of our Company."

Mr. Theodore added, "I am delighted to be joining Aeterna Zentaris at this exciting watershed in its transition to an operating specialty biopharmaceutical company. Clearly, the Company is on a path to successfully become a commercial-oriented entity and I look forward to working with the Aeterna Zentaris team in building a successful and sustainable, competitive organization."

Philip A. Theodore's Background

Mr. Theodore is a graduate of the University of Cincinnati College of Law, and holds a B.A. (Political Science) from the University of Tennessee at Chattanooga.

Before joining Aeterna Zentaris, Philip Theodore served as Vice President, General Counsel and Corporate Secretary of Zep Inc., a leading global supplier of consumable chemical packaged goods. Prior to joining Zep Inc., he served as Vice President of Corporate Development, Compliance and Legal for BioReliance, Inc. from September 2008 to April 2009; as Senior Vice President and General Counsel of John H. Harland Company from September 2006 to September 2007; and as Vice President, General Counsel and Corporate Secretary of Serologicals Corporation from 2004 through August 2006. Mr. Theodore also served as a partner in the corporate practice of King & Spalding, LLP, an Atlanta-based law firm, from 1986 through 2003.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

SOURCE Aeterna Zentaris Inc.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.